Home | Welcome to Contract Pharma   
Last Updated Saturday, May 23 2015


Financial Report: AbbVie

Published April 25, 2014
1Q Revenues: $4.6 billion (+5%)

1Q Earnings: $980 million (+1%)

Comments: Growth in the quarter was primarily driven by HUMIRA sales, up 18% to $2.6 billion, as well as key products including Synthroid (up 31% to $157 million), Creon (up 18% to $107 million) and Duodopa (up 32% to $52 million).Synagis sales were $324 million, up 3%. AndroGel sales were $254 million, up 6%. Kaletra sales were down 11% to $195 million. Niaspan and TriCor/Trilipix dropped 75% and 82% to $47 and $23 million, respectively, due to patent expiries. The company recently submitted its U.S. regulatory application for its interferon-free regimen for hepatitis C virus (HCV), and plans additional applications in the EU. The company expects U.S. commercialization in 2014 and European approval in early 2015.

blog comments powered by Disqus

Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On